Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Senti Biosciences (SNTI) Other Accumulated Expenses (2021 - 2025)

Senti Biosciences has reported Other Accumulated Expenses over the past 5 years, most recently at $73000.0 for Q4 2025.

  • For Q4 2025, Other Accumulated Expenses fell 83.14% year-over-year to $73000.0; the TTM value through Dec 2025 reached $73000.0, down 83.14%, while the annual FY2025 figure was $73000.0, 83.14% down from the prior year.
  • Other Accumulated Expenses for Q4 2025 was $73000.0 at Senti Biosciences, up from $62000.0 in the prior quarter.
  • Over five years, Other Accumulated Expenses peaked at $433000.0 in Q4 2024 and troughed at $3000.0 in Q1 2024.
  • A 5-year average of $93250.0 and a median of $53000.0 in 2023 define the central range for Other Accumulated Expenses.
  • Biggest five-year swings in Other Accumulated Expenses: tumbled 94.34% in 2024 and later skyrocketed 13933.33% in 2025.
  • Year by year, Other Accumulated Expenses stood at $111000.0 in 2021, then tumbled by 73.87% to $29000.0 in 2022, then tumbled by 68.97% to $9000.0 in 2023, then skyrocketed by 4711.11% to $433000.0 in 2024, then crashed by 83.14% to $73000.0 in 2025.
  • Business Quant data shows Other Accumulated Expenses for SNTI at $73000.0 in Q4 2025, $62000.0 in Q3 2025, and $53000.0 in Q2 2025.